Triple-Acting Aptamer–siRNA Reduces Breast Cancer Growth in Mice

Scientists at the Georgia Cancer Center have developed a chimeric anticancer molecule that simultaneously targets three key human epidermal growth factor receptors (HER) that are overexpressed in drug-resistant HER2 + breast cancers. When tested in mice carrying human breast tumors , the three-in-one aptamer–siRNA, known as H2EH3, specifically bound to the tumor cells, and interfered with HER2 and HER3 signaling, triggering cancer cell apoptosis and inhibiting tumor growth, with no evidenc